Glycerol phenylbutyrate - Horizon Pharma

Drug Profile

Glycerol phenylbutyrate - Horizon Pharma

Alternative Names: Glyceryl tri-(4-phenylbutyrate); GT4P; HPN-100; Ravicti

Latest Information Update: 17 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ucyclyd Pharma
  • Developer Horizon Pharma
  • Class Hepatoprotectants; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders; Hepatic encephalopathy; Spinal muscular atrophy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Inborn urea cycle disorders
  • No development reported Hepatic encephalopathy

Most Recent Events

  • 16 Jul 2018 Horizon Pharma receives two notices of allowance for glycerol phenylbutyrate in USA
  • 30 Jun 2018 Horizon Pharma settles litigation against Lupin over ANDA submission in USA
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top